echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Phase 3 clinical trial scheme of Moderna new crown vaccine of "medical fast reading society"

    Phase 3 clinical trial scheme of Moderna new crown vaccine of "medical fast reading society"

    • Last Update: 2020-06-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    < br / > Guangdong drugstore will start the second round of centralized collection; Novo Nordisk will purchase corvidia; new crown vaccine of Moderna will determine the three-phase clinical trial scheme; Amgen / Baiji Shenzhou cooperative double anti AMG 160 treatment of prostate cancer is approved clinical; Roche CPAM and TLR7 agonist combination therapy is approved clinical in China......< br / > < br / > the second round of centralized collection will be opened in Guangdong drugstore later this monthThe first round of centralized purchase of retail drugs in Guangdong Province involves 22 product regulations, with a total purchase amount of more than 110 million yuanMany manufacturers supply drugs to Guangdong retail pharmacies at a bid price even lower than the bid price with a volume of "4 + 7", with an average price drop of 61.2%(Southern Metropolis Daily) < br / > Wuhan Pharmaceutical Machinery Co., Ltdissued the notice on soliciting public opinions on the list of key monitoring and rational use drugs in Wuhan in 2020There are 30 varieties in the "list of key monitoring and rational drug use drugs in Wuhan in 2020"In addition to 20 varieties in the list of national key monitoring drugs, 10 varieties of Guhong injection, Shenxiong Injection, Luffa polypeptide injection, placenta polypeptide injection, safflower yellow pigment injection are added(Wuhan Pharmaceutical Machinery Co Mining Office) < br / > on November 11, the medical insurance bureau of Debao County, Guangxi Province issued a notice saying that according to the spirit of relevant documents, 29 kinds of special chronic diseases in outpatient clinics can be settled directly in the designated drugstore for the purchase costs of these diseasesAt present, depao branch of Wuzhou DASHENLIN chain drugstore Co., Ltdhas become the designated retail drugstore for outpatient special chronic diseases in the county(Medicare Bureau of Debao County, Guangxi) < br / > < br / > < br / > on November 11, Takeda said it would sell 18 over-the-counter and prescription drug combinations sold in the Asia Pacific region to South Korean pharmaceutical company celltrionThe deal totaled $278 million, including $266 million in cash advances and $12 million in potential milestone paymentsAs with previous divestitures, the rights to the drugs sold are outside Takeda's selected focus areas (Gastroenterology, rare diseases, plasma derived therapy, oncology and Neuroscience)(Sina Pharmaceutical News) < br / > Novo Nordisk, a Danish pharmaceutical company, announced that it would buy corvidia, a US private pharmaceutical company, for $725 millionIf all goes well, its shareholders could get up to $2.1 billion in revenueCorvidia was founded in 2015 and previously received a total of US $86 million in rounds a and B financing (US and Chinese drug sources) < br / > Lijin biology announced that it has reached a clinical trial cooperation agreement with its subsidiaries of MSD to evaluate the effect of lvgn6051, the second generation 4-1BB (CD137) agonist of Lijin biology, and keytruda, the PD-1 inhibitor of MSD, in the treatment of a variety of malignant tumors, including lung cancer, melanoma, gastrointestinal cancer and lymphoma with high MSI-H or dmmr-h (Medical Mission Hills) < br / > < br / > (Sina Medical News) < br / > 11, Pfizer announced that the FDA of the United States has approved nyvepria The specific indications are: Patients with non myelogenous malignant tumors who are receiving bone marrow suppressive anticancer drugs (such as chemotherapy) related to the clinically significant incidence of febrile neutropenia, reduce the incidence of infection, showing febrile neutropenia (Sina Medical News) < br / > the US FDA announced that it approved the listing of Vila bio's anti-CD19 monoclonal antibody uplizna (inebilizumab Cdon) for the treatment of patients with optic neuromyelitis pedigree disease These patients carry antibodies targeting AQP4 aquaporin This is the second innovative therapy approved by FDA to treat such patients (Wuxi apptec) < br / > Bristol Myers Squibb recently announced that its heavyweight PD-1 inhibitor, opdivo (nivolumab), has been approved by the U.S FDA In the treatment of unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) patients after chemotherapy with fluorouracil and platinum drugs, there is no discussion on the expression level of tumor PD-L1 (Wuxi apptec) < br / > Moderna announced that it has determined the design scheme of phase 3 clinical trial of its mRNA new crown vaccine based on the feedback of FDA The randomized, double-blind, placebo-controlled phase 3 trial is expected to involve about 30000 participants and will be conducted in collaboration with the National Institute of allergy and infectious diseases, affiliated to the National Institutes of health (Wuxi apptec) < br / > on November 11, the CDE official website showed that AMG 160, a new drug jointly declared by Amgen and Baiji Shenzhou, was approved for clinical use in the treatment of adult metastatic castration resistant prostate cancer Amg160 is a new kind of hle bite immunotherapy By combining with PSMA on tumor cells and CD3 on T cells, T cells can kill tumor cells directionally PSMA, a tumor associated antigen, is overexpressed on the surface of metastatic and hormone refractory prostate cancer cells (DXY insight database) < br / > regenerator announced today the launch of the first clinical trial of regn-cov2, a research-based double antibody cocktail therapy developed by the company for the prevention and treatment of covid-19 (Wuxi apptec) < br / > according to the information publicized by the drug evaluation center of the State Food and Drug Administration of China, Roche's ro7049389 and ro7020531 combined therapy has obtained many implied licenses for clinical trials in China, and the indications are combined therapy for chronic hepatitis B Ro7049389 is a kind of hepatitis B virus capsid protein assembly inhibitor, which can affect virus replication by inhibiting capsid protein assembly (Wuxi apptec) < br / > Haizheng pharmaceutical announced that the company has received the approval document for drug registration of donepezil hydrochloride orally disintegrating tablets approved and issued by the State Food and drug administration Donepezil hydrochloride orally disintegrating tablets are suitable for the treatment of mild or moderate Alzheimer's disease symptoms (AP) < br / > modern pharmaceutical announced that the State Food and Drug Administration approved clarithromycin tablets to pass the quality and efficacy evaluation of generic drugs Clarithromycin tablet is suitable for the infection caused by clarithromycin sensitive bacteria, such as rhinitis infection, lower respiratory tract infection, skin and soft tissue infection, acute otitis media, etc (Associated Press of Finance) < br / > on November 11, the application for imitating Acarbose Tablets of Liaoning xinshanyuan Pharmaceutical Co., Ltd was accepted by CDE In 2019, four types of generic listing applications of Acarbose Tablets of Beijing Fuyuan pharmaceutical were approved and deemed as having been evaluated, becoming the second domestic enterprise to obtain approval Up to now, there are still 4 types of imitated listing applications of 5 enterprises in the review and approval (minenet) < br / > 11, green leaf pharmaceutical announced that the clinical trial application of the innovative product irinotecan fluorouridine hydrochloride liposome injection has been officially accepted by CDE In the first half of 2020, LVYE pharmaceutical has obtained the clinical approval of a new class 1 drug, and there is also a McAb application for listing in the review and approval process, according to the data of minenet (minenet) < br / > one week after being approved for marketing, the price of baiyueze (zebuteni capsule), a new Baiji Shenzhou class 1 drug, flowed out at 11300 yuan per box and 22600 yuan per month for treatment, significantly lower than the price of 48600 yuan per month for the first generation of BTK inhibitors (DXY insight database)
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.